Neutrophils dominate the immune cell composition in non-small cell lung cancer
The response rate to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%. To improve this figure, several early phase clinical trials
Neutrophils dominate the immune cell composition in non-small cell lung cancer Read More »